Imunon (NASDAQ:IMNN) Posts Earnings Results, Beats Expectations By $0.33 EPS

Imunon (NASDAQ:IMNN) released its quarterly earnings data on Tuesday. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33, FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• OVATION 3 enrollment is ahead of plan, with approximately 0.5 patients per site per month versus the planned 0.3 and historical rates of about 0.2. Imunon said 35% of planned sites are active or being activated and that it remains on track for its enrollment timeline.
• IMNN-001 continues to show encouraging efficacy and safety signals. In the Phase II OVATION 2 study, median overall survival was 45.1 months versus 30.4 months for control, while the company reported no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events.
• Preliminary data from the small Phase II MRD study showed lower minimal residual disease positivity with IMNN-001 than control, 44% versus 67%, alongside higher circulating tumor DNA clearance and rates of no evidence of disease. The trial remains ongoing, and statistical significance is uncertain because it was not powered primarily for that outcome.
• Imunon ended the quarter with $6.9 million in cash and said its current resources support operations only through year-end, despite reducing quarterly operating cash use to $3.0 million. Management acknowledged that additional capital will be needed to fully fund OVATION 3 and general administrative expenses.
• The company completed a financing of up to $10 million using non-convertible preferred stock and secured promissory notes with no warrants, which management said was structured to limit dilution and financing overhang. It also highlighted a 20% year-over-year decline in general and administrative expenses.

Imunon Stock Performance

Shares of IMNN opened at $1.61 on Wednesday. The firm has a market cap of $6.76 million, a P/E ratio of -0.31 and a beta of 1.97. Imunon has a twelve month low of $1.47 and a twelve month high of $7.21. The firm’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $2.56.

Institutional Investors Weigh In On Imunon

An institutional investor recently bought a new position in Imunon stock. Armistice Capital LLC bought a new position in Imunon, Inc. (NASDAQ:IMNN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned 8.69% of Imunon at the end of the most recent quarter. 4.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on IMNN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Friday, July 17th. Maxim Group set a $10.00 target price on shares of Imunon and gave the stock a “buy” rating in a report on Friday, April 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.